Recent studies highlight promising molecular targets in cancer immunotherapy. Research published in BMC Cancer reveals T-LAK cell-originated protein kinase (TOPK) drives immune suppression in kidney renal clear cell carcinoma, suggesting new prognostic and therapeutic avenues. Separately, inhibition of proto-oncogene c-Abl impairs glioma cell proliferation and invasion, supporting its potential as a target for glioma treatments. These findings offer new molecular insights that could steer innovative immunotherapeutic strategies.